Cargando…
Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy
Improved risk stratification of patients suspected of prostate cancer prior to biopsy continues to be an unmet clinical need. ExoDx Prostate (IntelliScore) “EPI” is a non-invasive urine test utilizing RNA from exosomes to provide a risk score that correlates with the likelihood of finding high grade...
Autores principales: | Kretschmer, Alexander, Kajau, Holger, Margolis, Eric, Tutrone, Ronald, Grimm, Tobias, Trottmann, Matthias, Stief, Christian, Stoll, Georg, Fischer, Christian A., Flinspach, Claudia, Albrecht, Anja, Meyer, Lisa, Priewasser, Tina, Enderle, Daniel, Müller, Romy, Torkler, Phillipp, Alter, Jason, Skog, Johan, Noerholm, Mikkel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938406/ https://www.ncbi.nlm.nih.gov/pubmed/35314720 http://dx.doi.org/10.1038/s41598-022-08608-z |
Ejemplares similares
-
Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome
por: Kretschmer, Alexander, et al.
Publicado: (2022) -
Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies
por: Margolis, Erik, et al.
Publicado: (2021) -
Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL
por: Tutrone, Ronald, et al.
Publicado: (2020) -
A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy
por: McKiernan, James, et al.
Publicado: (2020) -
Extracellular vesicles from plasma have higher tumour RNA fraction than platelets
por: Brinkman, Kay, et al.
Publicado: (2020)